Screener
Arbutus Biopharma Corporation ABUS Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (17) | (28) |
| Foreign exchange (loss) gain | (11) | 4 |
| Total other income | 787 | 1,173 |
| Net income (loss) | $169,695 | $(24,526) |
| Net income (loss) per common share | ||
| Basic | $0.88 | $(0.13) |
| Diluted | $0.87 | $(0.13) |
| Weighted average number of common shares |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's net income?
- Arbutus Biopharma Corporation (ABUS) reported net income of $169.7M in Q1 2026.
- How has Arbutus Biopharma Corporation's net income changed year-over-year?
- Arbutus Biopharma Corporation's net income increased by 791.9% year-over-year, from -$24.53M to $169.7M.
- What is the long-term trend for Arbutus Biopharma Corporation's net income?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's net income has grown at a -18.6% compound annual growth rate (CAGR), from -$76.25M to -$33.5M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Arbutus Biopharma Corporation's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude